The Company
Kymeris refers to Kymeris Therapeutics (Canada) and to Kymeris Santé (France), established in the first quarter of 2017.
- Funded by the founders and by non-dilutive financing the total economic value of which surpasses USD 6.5 million as of 2019
- The company had operated in Stealth Mode until intellectual property and an exclusive license agreement were secured in 2019.
- New funding will be used to engage in clinical development (pre-IND) and to explore partnerships for drug delivery with one or several pharmaceutical companies.
- Our intent is to reinforce platform research in Europe and to advance Clinical Development in the United States, where capital, human resources and industry dynamism would most efficiently consolidate the lead positioning of this novel immunotherapy platform.
- Platform development will continue in France, where expertise in cellular science and cancer immunology has been combined in a multifunctional research group of remarkable skill and efficiency
A Multi-Disciplinary Research Team
Some fifteen scientists, including eight PhDs devote between 20%-100% of their time to the advancement of this technology. Their Fields of Expertise include: Immunology, Oncology, Molecular biology, Microbiology and Genetic Engineering. In addition, clinical oncologists and researchers in Europe and planned in N. America complement the range of competences required to advance as efficiently as possible into Clinical Development.
Our People
Investor-Founders
Richard McCrae
Mr. McCrae has variously occupied senior roles in international consulting, investment banking and diplomacy, in Europe, North America, the Middle East and Asia. He headed Bank of Nova Scotia’s (through ScotiaMcLeod) continental European investment banking franchise based in Paris. For 10 years he was an advisor/ gatekeeper of global investment for a private European $ 1 Billion+ pharmaceutical holding company and by delegation Chairman or CEO of numerous of its portfolio investments in biotechnology.
Gordon Lee, MD MBA
Dr. Lee graduated from medicalschool in the UK with post-gradraduate training in France. He subsequently completed an MBA at Wharton (University of Pennsylvania).
His business career began at Merck in the US, followed in France, as head of business development for GE Medical Systems Europe.
R&D Leaders
Isabelle Dimier-Poisson, PhD
University of Tours, FR.
Deputy Director, National Infections & Public Health Research Center (ISP UMR), a Tours University-INRAE shared research team. INRAE is the largest European research body focused on Agriculture, Food and Environment.
Dr. Dimier-Poisson is an authority on the Immunology of Infectious Diseases. She is both Professor of Pharmaceutical Sciences at Tours University and also Deputy Director of UMR ISP, a joint research center of the INRAE & Tours University with combined 150 staff, including 75 researchers, organized into 12 research teams . She has assembled a dynamic research team, now 15 researchers strong, that focuses on Kymeris-related experiments in immuno-oncology
The INRAE (French: Institut National de la Recherche – Agriculture, Alimentation et Environnement) is the #1 center for agriculture, food and environmental research in Europe. The University of Tours (French: Université de Tours), founded in 1969, has a modern campus of some 28,000 and is the biggest university in the Région Centre Val-de-Loire of France, location of INRAE’s Regional Research Centre focusing on microbial infections relating to Public Health.